Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34

Annals of the Rheumatic Diseases

Volumn 56, Issue 12, 1997, Pages 716-722

  Hoffmann, Jörg C ^a,b   Herklotz, Claudia ^a   Zeidler, Henning ^a   Bayer, Bettina ^a   Rosenthal, Herbert ^a   Westermann, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; DEXAMETHASONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX 34; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DESTRUCTION; CLINICAL FEATURE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE DEPLETION; MEMORY CELL; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS;

EID: 0031415047     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.56.12.716     Document Type: Article

References (30)

1. Crofford LJ, Wilder RL. Arthritis and autoimmunity in animals. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993: 525-41.
2. Taurog JD, Argentieri DC, McReynolds RA. Adjuvant arthritis. Methods Enzymol 1988;162:339-55.
3. Issekutz AC, Meager A, Otterness I, Issekutz TB. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 1994;97:26-32.
4. Yoshino S, Schlipkoter E, Kinne R, Hunig T, Emmrich F. Suppression and prevention of adjuvant arthritis in rats by a monoclonal antibody to the alpha/beta T cell receptor. Eur J Immunol 1990;20:2805-8.
5. Issekutz AC, Issekutz TB. Quantitation and kinetics of polymorphonuclear leukocyte and lymphocyte accumulation in joints during adjuvant arthritis in the rat. Lab Invest 1991; 64:656-63.
6. Halloran MM, Szekanecz Z, Barquin N, Haines GK, Koch A E. Cellular adhesion molecules in rat adjuvant arthritis. Arthritis Rheum 1996;39:810-9.
7. Alarcon GS, Lopez Mendez A, Walter J, Beerbooms AM, Russell AS, Furst DE, et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol 1992;19:1868-73.
8. Lopez Mendez A, Daniel WW, Reading JC, Ward JR, Alarcon GS. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993;36:1364-9.
9. Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-9.
10. Hoffmann JC, Herklotz C, Zeidler H, Bayer B, Westermann J. Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 downmodulation. Clin Exp Immunol 1997;110:63-71.
11. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2762-6.
12. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992;175: 1135-8.
13. Westermann J, Nagahori Y, Walter S, Heerwagen C, Miyasaka M, Pabst R. B and T lymphocyte subsets enter peripheral lymph nodes and Peyer's patches without preference in vivo: no correlation occurs between their localization in different types of high endothelial venules and the expression of CD44, VLA-4, LFA-1, ICAM-1, CD2 or L-selectin. Eur J Immunol 1994;24:2312-6.
14. Hocherg Y, Tamhane AC. Multiple comparison procedures. New York: John Wiley, 1987.
15. Meacock SC, Brandon DR, Billingham ME. Arthritis in Lewis rats induced by the non-immunogenic adjuvant CP20961: an immunohistochemical analysis of the developing disease. Ann Rheum Dis 1994;53:653-8.
16. Zvaifler NJ, Firestein GS. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.
17. Kohashi O, Pearson CM, Tamaoki N, et al. Role of thymus for N-acetyl muramyl-L-alanyl-D-isoglutamine-induced polyarthritis and granuloma formation in euthymic and athymic nude rats or in neonatally thymectomized rats. Infect Immun 1981;31:758-66.
18. Pelegri C, Paz Morante M, Castellote C, Castell M, Franch A. Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25. Cell Immunol 1995;165:177-82.
19. Pelegri C, Morante MP, Castellote C, Franch A, Castell M. Treatment with an anti-CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis. Clin Exp Immunol 1996;103:273-8.
20. Sternberg EM, Wilder RL. Corticosteroids. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993: 665-82.
21. Axelrod L. Glucocorticoids. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. Philadelphia: Saunders, 1993: 779-96.
22. Hirahara H, Tsuchida M, Watanabe T, Hanawa H, Matsumoto Y, Abo T, et al. Long-term survival of cardiac allografts in rats treated before and after surgery with monoclonal antibody to CD2. Transplantation 1995; 59:85-90
23. Reed JC, Tadmori W, Kamoun M, Koretzky G, Nowell PC. Suppression of interleukin 2 receptor acquisition by monoclonal antibodies recognizing the 50 KD protein associated with the sheep erythrocyte receptor on human T lymphocytes. J Immunol 1985;134:1631-9.
24. van der Merwe PA, McPherson DC, Brown MH, Barclay AN, Cyster JG, Williams AF, et al. The NH2-terminal domain of rat CD2 binds rat CD48 with a low affinity and binding does not require glycosylation of CD2. Eur J Immunol 1993;23:1373-7.
25. Arvieux J, Jefferies WA, Paterson DJ, Williams AF, Green JR. Monoclonal antibodies against a rat leucocyte antigen block antigen-induced T-cell responses via an effect on accessory cells. Immunology 1986;58:337-42.
26. Seaman WE, Eriksson E, Dobrow R, Imboden JB. Inositol trisphosphate is generated by a rat natural killer cell tumor in response to target cells or to crosslinked monoclonal antibody OX-34: possible signaling role for the OX-34 determinant during activation by target cells. Proc Natl Acad Sci USA 1987;84:4239-43.
27. Gückel B, Berek C, Lutz M, Altevogt P, Schirrmacher V, Kyewski BA. Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med 1991;174:957-67.
28. Hershkoviz R, Gilat D, Miron S, Mekori YA, Aderka D, Wallach D, et al. Extracellular matrix induces tumour necrosis factor-alpha secretion by an interaction between resting rat CD4+ T cells and macrophages. Immunology 1993;78:50-7.
29. Barlow AK, Like AA. Anti-CD2 monoclonal antibodies prevent spontaneous and adoptive transfer of diabetes in the BB/Wor rat. Am J Pathol 1992;141:1043-51.
30. Jung S, Toyka K, Hartung HP. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 1995;25:1391-8.